Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Patch for COVID-19 Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 18 years of age or female ≥ 55 years of age~* Documentation of COVID19 positivity or the presence of one or more of the following new onset (\<7 days) clinical features defining presumptive COVID19~  1. fever of \>100.5°F or 38°C~ 2. shortness of breath~ 3. cough~ 4. radiologic evidence of pneumonia~* Able to provide informed consent~* Able to be contacted by telephone for follow-up~Exclusion Criteria:~* Currently receiving estrogen based hormonal therapy~* Abnormal genital bleeding~* Protein C or Protein S deficiency~* Pre-existing liver impairment (e.g. Hepatitis C, cirrhosis)~* History of anaphylactic reaction or angioedema with Climara~* Receiving lamotrigine therapy~* Subjects with known past diagnosis of estrogen receptor positive breast cancer or endometrial cancer~* Subjects with severe hypoxia at risk for acute intubation in ED~* History of stroke~* Any history of thromboembolic event including deep vein thrombosis or pulmonary emboli~* Current use of St. John's Wort~* Males on testosterone~* History of myocardial infarction, cardiac stents, or active angina

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Estradiol Patch
- Control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).